Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):331–342. doi: 10.1128/aac.28.2.331

Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

L J Chalkley, H J Koornhof
PMCID: PMC180242  PMID: 2939797

Abstract

A derivative of quinolinecarboxylic acid, ciprofloxacin (BAY o 9867) was found to be an effective bactericidal agent against Pseudomonas aeruginosa and Escherichia coli. A bactericidal effect was achieved immediately after the addition of ciprofloxacin. At a concentration of 0.5 micrograms/ml, culture viability was reduced from 5 X 10(5) to about 5 X 10(3) CFU/ml within 15 min, and at 0.1 micrograms/ml, a greater than 10-fold reduction in viability resulted during the first hour after exposure. This bactericidal activity observed during the lag phase in Mueller-Hinton broth was also demonstrated in a nongrowing system. The antibiotics used in comparative studies, i.e., tobramycin, aztreonam, cefotaxime, and azlocillin, did not show this initial bactericidal activity, and ciprofloxacin prevented culture regrowth at lower concentrations. Staphylococcus aureus was not as susceptible to ciprofloxacin; killing occurred at a concentration of 0.5 micrograms/ml only after the onset of exponential growth in the control culture. Synergistic interactions were observed with ciprofloxacin in combination with tobramycin and azlocillin against P. aeruginosa and with cefotaxime and tobramycin against E. coli.

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chartrand S. A., Scribner R. K., Weber A. H., Welch D. F., Marks M. I. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound. Antimicrob Agents Chemother. 1983 May;23(5):658–663. doi: 10.1128/aac.23.5.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cook T. M., Deitz W. H., Goss W. A. Mechanism of action of nalidixic acid on Escherichia coli. IV. Effects on the stability of cellular constituents. J Bacteriol. 1966 Feb;91(2):774–779. doi: 10.1128/jb.91.2.774-779.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cozzarelli N. R. DNA gyrase and the supercoiling of DNA. Science. 1980 Feb 29;207(4434):953–960. doi: 10.1126/science.6243420. [DOI] [PubMed] [Google Scholar]
  5. Crumplin G. C., Kenwright M., Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother. 1984 May;13 (Suppl B):9–23. doi: 10.1093/jac/13.suppl_b.9. [DOI] [PubMed] [Google Scholar]
  6. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hallander H. O., Dornbusch K., Gezelius L., Jacobson K., Karlsson I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother. 1982 Nov;22(5):743–752. doi: 10.1128/aac.22.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irikura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980 Feb;17(2):103–108. doi: 10.1128/aac.17.2.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Khan M. Y., Gruninger R. P., Nelson S. M., Klicker R. E. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother. 1982 May;21(5):848–851. doi: 10.1128/aac.21.5.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. King A., Shannon K., Phillips I. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Apr;13(4):325–331. doi: 10.1093/jac/13.4.325. [DOI] [PubMed] [Google Scholar]
  11. Nakamura S., Minami A., Katae H., Inoue S., Yamagishi J., Takase Y., Shimizu M. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother. 1983 May;23(5):641–648. doi: 10.1128/aac.23.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Neu H. C., Labthavikul P. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1982 Jul;22(1):23–27. doi: 10.1128/aac.22.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shungu D. L., Weinberg E., Gadebusch H. H. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrob Agents Chemother. 1983 Feb;23(2):256–260. doi: 10.1128/aac.23.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Van Caekenberghe D. L., Pattyn S. R. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984 Apr;25(4):518–521. doi: 10.1128/aac.25.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES